Multiple GSH adducts of the oxidative products of nomifensine (M1-M9) in human hepatocytes and liver microsomes have been identified recently. The current study reports three new types of monooxygenated metabolites of nomifensine identified in human liver microsomes: C-linked hydroxylated metabolites with modifications at the A ring (H1 and H4), an N-hydroxylamine (H6), and nomifensine N-oxides (H7 and H8). GSH conjugate formation in incubates containing cDNA-expressed P450s and GSH suggests that nomifensine GSH-sulfinamides (M1 and M2) are formed through the reaction between GSH and the oxidative product of H6. C-linked GSH conjugates M3, M4, M5, and M6 are probably formed via nomifensine benzoquinone imine intermediates via H4 and/or nomifensine epoxides. C-linked GSH conjugates M7, M8, and M9 are probably formed through similar mechanisms via H1. Nomifensine N-oxides do not form reactive metabolites that react with GSH. In vitro metabolism studies using a panel of cDNA-expressed human P450 and flavin monooxygenase (FMO) isoforms (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, FMO1, FMO3, and FMO5) indicated that CYP3A4, CYP2C19, and CYP2B6 generate the largest quantities of H1, H4, and H6, respectively. H7 and H8 are formed almost exclusively by FMOs. The contribution of the individual P450s involved in the formation of H1, H4, and H6 in human liver microsomes was confirmed by the inhibition of product formation by monoclonal anticytochrome 450 antibodies. These results showed that CYP3A4 and CYP2B6 contributed primarily to the formation of H1 and H6, respectively. CYP2C19 and CYP1A2 seemed to contribute significantly to the formation of H4.
Introduction
Nomifensine (8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline maleate) (Fig. 1) , an effective antidepressant, was withdrawn from the market because of hemolytic anemia and kidney and liver toxicity (Nielsen and Lund, 1981; Kummer et al., 1985; MuellerEckhardt, 1985, 1986; Salama et al., 1991; Stonier and Edwards, 2002) . Bioactivation has been postulated as a potential mechanism for its immune toxicity because of the observation that nomifensine induced the production of antibodies and/or autoantibodies directed against drug-and/or metabolite-red blood cell conjugates in patients who developed immune hemolytic anemia while receiving the drug Mueller-Eckhardt, 1985, 1986; Salama et al., 1991; Stonier and Edwards, 2002) .
Our recent studies showed that nomifensine GSH-sulfinamides (Fig. 1, M1 and M2) were formed in incubations of nomifensine with human and animal hepatocyte preparations and in NADPH-plus GSH-supplemented liver microsomes (Yu et al., 2010) . Although oxidative modifications to the aniline nitrogen were suggested by this result, nomifensine N-hydroxylamine and its sequential oxidation products have not been described in the literature. Identification of the nomifensine N-hydroxylamine metabolite would help confirm the bioactivation pathway that leads to formation of nomifensine GSHsulfinamides.
Our previous studies also showed that multiple C-linked GSH adducts (Fig. 1 , M3-M9) were formed through nomifensine arene oxidation followed by GSH conjugation (Yu et al., 2010) . However, these studies did not provide insight into the nature of the reactive intermediates formed after oxidative metabolism of nomifensine because of the lack of characteristic mass fragment ions for the GSH adducts. It is well known that oxidation at the arene ring of aromatic amines can lead to the formation of benzoquinone imine reactive metabolites. Because nomifensine oxidative metabolites with modifications in the A ring have not been reported, this route of bioactivation also was investigated by metabolite identification and by GSH trapping studies.
Reports of the characterization of human metabolites of nomifensine (Kellner et al., 1977; Heptner et al., 1978; Hornke et al., 1980; Lindberg and Syvälahti, 1986 ) revealed multiple hydroxylated modifications to the phenyl ring (Fig. 1 , nomifensine hydroxylated metabolites I, II, and III). Our previous study (Yu et al., 2010) excluded the possibility of a bioactivation pathway via a potential reactive ortho-quinone intermediate (through the oxidation of the catechol at the C ring) (Obach and Dalvie, 2006) on the basis of the fact that only one oxygen atom is incorporated in the GSH adducts. However, our previous results could not address the possibility of a quinone-methide intermediate (the oxidative product of I) as the reactive metabolite (Kalgutkar and Soglia, 2005) . Therefore, this potential bioactivation pathway also was investigated.
Furthermore, the oxidation at the nitrogen atom in the 1,2,3,4-tetrahydroisoquinoline ring of nomifensine that leads to the formation of N-oxides has not been reported. We investigated this metabolic pathway and further evaluated the possibility that these N-oxides may form reactive metabolites that react with GSH.
Finally, the enzymes involved in the formation of any of these nomifensine oxidative intermediates remain unknown. Identifying the enzymes that catalyze the bioactivation pathways of nomifensine that lead to the formation of GSH conjugates would significantly help us understand the mechanisms of nomifensine toxicities observed in vivo.
The present study describes three new types of nomifensine monooxygenated metabolites identified by liquid chromatography (LS)-tandem mass spectrometry (MS/MS) from incubations of nomifensine with human liver microsomes supplemented with NADPH. Relationships among these monooxygenation pathways and GSH adduct formation were investigated. Finally, the P450 and FMO isoforms that are potentially responsible for the formation of these metabolites were identified using cDNA-expressed human P450s and FMOs and monoclonal anti-P450 antibodies. Our findings raise the possibility that more than one nomifensine bioactivation pathway may lead to the clinical observations of nomifensine toxicities. The toxicity profile of nomifensine may be further complicated by the fact that some bioactivation pathways are catalyzed primarily by a single P450 isozyme that is polymorphically expressed and inducible.
Materials and Methods
Chemicals and Materials. Nomifensine, glutathione (reduced, GSH), magnesium chloride, ␤-nicotinamide adenine dinucleotide 2Ј-phosphate (reduced, NADPH), deuterium oxide, formic acid-d 2 (DCO 2 D), 1-aminobenzotriazole, and labetalol were obtained from Sigma-Aldrich (St. Louis, MO). Pooled human liver microsomes from 33 donors (protein concentration 20 mg/ml), Supersomes prepared from baculovirus/insect cells expressing human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, FMO1, FMO3, and FMO5, and monoclonal antibodies to CYP1A2, CYP3A4, CYP2B6, and CYP2C19, were purchased from BD Biosciences (San Jose, CA). The specificity and the selectivity of the monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 are available (website of BD Biosciences). The monoclonal antibody to CYP3A4 used in this study also shows some inhibition of CYP3A5. 4-(8-Amino-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenol (the 4-hydroxylated metabolite of nomifensine, I) was obtained from AstraZeneca Pharmacy. The 5 mM stock solution of nomifensine used for incubations was prepared using 30% (v/v) acetonitrile-water as the solvent. All other reagents and solvents were of the highest quality available.
Identification of Monooxygenated Metabolites and GSH Conjugates of Nomifensine in Incubations of Nomifensine with Human Liver Microsomes. The monooxygenated metabolite and GSH conjugate profiles of nomifensine were investigated with human liver microsomes. Nomifensine (40 M) was mixed with human liver microsomes (0.5 mg/ml), MgCl 2 (10 mM), and potassium phosphate buffer (pH 7.4) in a final volume of 200 l. The mixture was preincubated at 37°C for 5 min. The reactions were initiated by the addition of NADPH (final concentration was 1 mM). Control experiments were conducted in the absence of NADPH. After incubation for 30 min, the reactions were terminated by the addition of 2 volumes of ice-cooled acetonitrile, followed by vortexing and centrifugation at 14,000 rpm (MIKRO 22R centrifuge; Andreas Hettich GmbH and Co. KG, Tuttlingen, Germany) at 4°C for 6 min to pellet the precipitated protein. The resulting supernatant was removed quickly and evaporated to dryness under a steady stream of nitrogen at room temperature. The residue was reconstituted in 20% (v/v) ice-cooled acetonitrile-water and analyzed by LC-MS/MS immediately. To study GSH conjugate profiles, incubations were performed in the presence of GSH (10 mM) to capture any reactive species (Yu et al., 2010) . To study the relative contributions of P450 and FMO enzymes to the formation of nomifensine monooxygenated metabolites H7 and H8, incubations were performed with human liver microsomes (1 mg/ml) preincubated with 1-aminobenzotriazole (1 mM) and NADPH (5 mM) for 20 min to inhibit P450 activity. The reactions were initiated by the addition of nomifensine (final concentration was 40 M). Control experiments were conducted in the presence or absence of NADPH.
Identification of Monooxygenated Metabolites and GSH Conjugates of Nomifensine in Incubations of Nomifensine with cDNA-Expressed Human FMO Isoforms. The monooxygenated metabolite and GSH conjugate profiles of nomifensine were investigated with cDNA-expressed human FMO isoforms. Nomifensine (100 M) was mixed with human FMO Supersomes (FMO1, FMO3, or FMO5) (100 g), MgCl 2 (10 mM), and glycine buffer (50 mM, pH 9.5) in a final volume of 250 l. The mixture was preincubated at 37°C for 5 min. The reactions were initiated by the addition of NADPH (final concentration was 1 mM) and terminated after 30 min by the addition of ice-cooled acetonitrile. Control experiments were conducted in the absence of NADPH. The analytical samples were prepared as above. To study GSH conjugate profiles, incubations were performed in the presence of GSH (10 mM) to capture any reactive species.
Incubation of Nomifensine with Microsomes from Baculovirus/Insect Cells Expressing Human CYP450s (Supersomes) and the Preparation of Calibration Curves to Quantify the Nomifensine Monooxygenated Metabolites (H1, H4, and H6). The incubation mixture contained Supersomes (100 pmol protein/ml), MgCl 2 (10 mM), NADPH (1 mM), and nomifensine (100 M) in a final volume of 200 l of potassium phosphate buffer (100 mM, pH 7.4) for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5 reactions. A mixture without NADPH was preincubated at 37°C for 5 min, and the reaction was initiated by the addition of NADPH. After incubation for 30 min, the reaction was terminated by the addition of 400 l of ice-cooled acetonitrile containing 0.15 M labetalol. The analytical samples were prepared as above. The residue was reconstituted in 200 l of 20% (v/v) ice-cooled acetonitrile-water.
The samples for calibration curves to quantify H1, H4, and H6 were prepared through a series of dilutions of the nomifensine monooxygenated metabolites generated in the corresponding recombinant enzyme systems. Metabolites H1, H4, and H6 were generated through the incubation of nomifensine with recombinant CYP3A4, CYP2C19, and CYP2B6, respectively. The incubation mixture contained Supersomes (100 pmol protein/ml CYP3A4, CYP2C19, or CYP2B6), MgCl 2 (10 mM), NADPH (1 mM), and nomifensine (100 M) in a final volume of 200 l of potassium phosphate buffer (100 mM, pH 7.4). Three incubations were performed for each isoform. A mixture without NADPH was preincubated at 37°C for 5 min, and the reaction was initiated by the addition of NADPH. After incubation for 30 min, the reaction was terminated by the addition of 400 l of ice-cooled acetonitrile followed by vortexing and centrifugation. The pooled supernatant from the three incubations was evaporated to dryness under a steady stream of nitrogen at room temperature. The residue was reconstituted in 480 l of 5% ice-cooled acetonitrile-water. Serial dilutions of the metabolites were obtained by adding 1, 2, 6.25, 12.5, 25, 50, 100 , and 150 l of the reconstituted mixture to 199, 198, 193.75, 187.5, 175, 150, 100 , and 50 l of 5% ice-cooled acetonitrile-water, respectively. Labetalol in ice-cooled acetonitrile (50 l of 1.5 M) was added to each sample as an internal standard before analysis by LC-MS/MS. To prepare the nondiluted sample, 40 l of the reconstituted mixture was added to 10 l of 1.5 M labetalol in ice-cooled acetonitrile. The incubations were performed in duplicate and analyzed separately.
Inhibition of Production of Nomifensine Monooxygenated Metabolites in Human Liver Microsomes Using Monoclonal Antibodies and the Preparation of Calibration Curves. The assays were performed using human liver microsomes as the enzyme source and nomifensine as the substrate. The incubation mixture contained human liver microsomes (0.5 mg protein/ml), MgCl 2 (10 mM), NADPH (1 mM), nomifensine (100 M), and monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, or CYP3A4 in a final volume of 200 l of potassium phosphate buffer (100 mM, pH 7.4). Five microliters of microsomes (20 mg protein/ml) and 10 l of monoclonal antibody (CYP1A2, CYP2B6, CYP2C19, or CYP3A4) or 100 mM phosphate buffer as control were mixed and incubated for 20 min on ice. Then 181 l of potassium phosphate buffer mixture (pH 7.4) containing NADPH (final concentration 1 mM) was added to that mixture and incubated at 37°C for 5 min. The reaction was initiated by the addition of 4 l of the 5 mM nomifensine stock solution. Reactions were terminated after 30 min by the addition of 400 l of ice-cooled acetonitrile containing 0.15 M labetalol (internal standard). The analytical samples were prepared as above. The residue was reconstituted in 100 l of 20% ice-cooled acetonitrile-water. These assays were performed in triplicate.
The samples for calibration curves to quantify H1, H4, and H6 were prepared through a series of dilutions of these metabolites generated in the same human liver microsomal incubation mixture. The incubation mixture contained human liver microsomes (0.5 mg protein/ml), MgCl 2 (10 mM), NADPH (1 mM), and nomifensine (100 M) in a final volume of 200 l of potassium phosphate buffer (100 mM, pH 7.4). Nomifensine was mixed with human liver microsomes, MgCl 2 , and potassium phosphate buffer. This mixture was preincubated at 37°C for 5 min. The reactions were initiated by the addition of NADPH (final concentration was 1 mM). Five incubations were generated. Reactions were terminated by the addition of 400 l of ice-cooled acetonitrile followed by vortexing and centrifugation. The pooled supernatant from the five incubations was evaporated to dryness under a steady stream of nitrogen at room temperature. The residue was reconstituted in 400 l of 5% ice-cooled acetonitrile-water. Serial dilutions of the metabolites were generated by adding 2, 6.25, 12.5, 25, 50, 100, and 150 l of the reconstituted mixture to 198, 193.75, 187.5, 175, 150, 100 , and 50 l of 5% ice-cooled acetonitrile-water, respectively. Labetalol (50 l of 1.5 M, internal standard) in ice-cooled acetonitrile was added to each sample before it was analyzed by LC-MS/MS. To prepare the nondiluted sample, 40 l of the reconstituted mixture was added to 10 l of 1.5 M labetalol in ice-cooled acetonitrile. The incubations were performed in duplicate and analyzed separately.
Inhibition of Nomifensine GSH Adduct Formation in Human Liver Microsomes Using Monoclonal Antibodies and the Preparation of Calibration Curves. The incubations were performed in human liver microsomes in the presence of GSH (10 mM) using the same method as above. The residue was reconstituted in 50 l of 20% (v/v) ice-cooled acetonitrile-water and analyzed by LC-MS/MS. These assays were performed in triplicate.
The samples for calibration curves to quantify the nomifensine GSHsulfinamides (M1 and M2 as total) were prepared through a series of dilutions of the sulfinamides generated in the same human liver microsomes in the presence of GSH. The incubation mixture contained human liver microsomes (0.5 mg protein/ml), MgCl 2 (10 mM), NADPH (1 mM), GSH (10 mM), and nomifensine (100 M) in a final volume of 200 l of potassium phosphate buffer (100 mM, pH 7.4). Nomifensine was mixed with human liver microsomes, MgCl 2 , GSH, and potassium phosphate buffer. The mixture was preincubated at 37°C for 5 min. The reactions were initiated by the addition of NADPH (final concentration was 1 mM). Ten incubations were generated. Reactions were terminated by the addition of 400 l of ice-cooled acetonitrile, followed by vortexing and centrifugation. Pooled supernatant from the 10 incubations was evaporated to dryness under a steady stream of nitrogen at room temperature. The residue was reconstituted in 400 l of 5% ice-cooled acetonitrile-water. Serial dilutions of the metabolites were obtained by using the same method as above. The incubations were performed in duplicate and analyzed separately.
LC-MS/MS Analysis. Metabolite profiling and identification in the microsomal and cDNA-expressed human P450 and FMO incubations were achieved by separating the metabolites on an Acquity UPLC HSS T3 column (2.1 ϫ 100 mm, 1.8 m, with a VanGuard HSS T3 1.8-m guard column; Waters, Milford, MA) at 15°C. The mobile phase consisted of water (solvent A, containing 0.1% formic acid) and acetonitrile (solvent B, containing 0.1% formic acid) and was delivered at 0.2 ml/min. The initial composition of solvent B was maintained at 10% for 3 min and then increased in a linear manner to 70% at 13 min and 90% at 16 min. It was then maintained at 90% solvent B for 3 min and finally decreased to 10%. The column was allowed to equilibrate at 10% solvent B for 4 min before the next injection. The deuterated mobile phase consisted of phase A (deuterium oxide containing 0.1% formic acid-d 2 ) and phase B (acetonitrile containing 0.1% formic acid-d 2 ) running in a similar gradient (Supplemental Figs. S1 and S2). Sample temperature was kept at 5°C.
Mass spectrometric analyses were performed on a Thermo LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA), which was interfaced to an Acquity UPLC system (Waters). MS analyses were conducted using a standard electrospray ionization source operating in positive ionization mode. Source operating conditions were 4.0 kV spray voltage, 275°C heated capillary temperature, 14 V capillary voltage, and sheath and auxiliary gas flow at 40 and 10 arbitrary units of the manufacturer, respectively. Data were centroid. The full scan and MS/MS product ion scan mass spectra were acquired at a resolving power of 30,000 (at m/z 400). The product ion scan activation parameters used an isolation width of 2 Da (for fragments with m/z values that were 1 Da different from the intended fragment, the isolation width was set to 1 Da), normalized collision energy of 30 to 40% and an activation time of 30 ms. The quantitative analysis was performed by measurement of the peak area of the extracted ion chromatograms using full-scan mode and a mass window with an error of 5 ppm centering on the theoretical m/z of the monooxygenated metabolites (m/z 255.1492), GSH conjugates (doubly charged ion at m/z 280.6126), and labetalol (m/z 329.1860). Calibration of the instrument was performed using the standard LTQ calibration mixture with caffeine, the peptide L-methionyl-arginyl-phenylalanyl-alanine acetate, and Ultramark 1621 dissolved in an acetonitrile-methanol-water solution containing 1% (v/v) acetic acid. The predicted chemical formulae and calculated accurate mass were obtained from ChemDraw Ultra 8.0 (CambridgeSoft Corporation, Cambridge, MA) based on the proposed fragmentation pathways and the putative fragment structures. The data were filtered in Qual Browser (Thermo Fisher Scientific) based on accurate mass thresholds. In addition, the Qual Browser chemical formula calculator was used to provide chemical formulae and experimental error values for molecular ions and product ions of nomifensine and its metabolites. Fragmentations were proposed based on plausible protonation sites, subsequent isomerization, and even electron species, as well as bond saturation. Comparison between the parent and metabolite product ion spectra further aided in the identification of metabolite structures and site(s) of modifications in the parent molecule.
Data Handling. All of the calculated experimental values are expressed as means Ϯ S.D. of three experiments throughout Results and Discussion. The calibration curves were generated by the average of values of two experiments for each data point. Calibration curves for the quantitation of the metabolites were obtained by fitting the linear equation to the experimental data using linear regression (Prism 4; GraphPad Software Inc., San Diego, CA). Linear regression was assessed from S.E., 95% confidence intervals, and r 2 . In this study, the absolute concentrations of the metabolites (H1, H4, H6, M1, and M2) in the incubation mixtures could not be determined because of the lack of synthetic standards. However, the relative activity of the P450s can still be ranked by comparing the concentration of a metabolite in a sample with the concentration of the same metabolite in the sample that has the highest mass response (and therefore the assumed highest concentration) under the same experimental conditions. The calibration curves were prepared by systematic dilution of the incubation mixture that has the highest mass response for the specific metabolite. The relative formation activity of the cDNAexpressed human P450s toward the production of a metabolite could be calculated according to eq. 1. When the experimental conditions (protein concentration and incubation time) of a sample are the same as those in the sample that has the highest mass response, eq. 1 can be simplified as the ratio of concentrations in two samples: (1) By using the same method, the enzymatic activity remaining (percent) in human liver microsomes in the presence of the corresponding anti-P450 antibody was calculated according to eq. 2:
Enzyme activity remaining (%) ϭ
Metabolite concentration with antibody to P450s Metabolite concentration without antibody to P450s ϫ 100 (2) The inhibition ratio was calculated according to eq. 3:
Inhibition ratio (%) ϭ 100 Ϫ enzymatic activity remaining (%) (3)
Results
Nomifensine Monooxygenated Metabolite Profile in Human Liver Microsomes. Table 1 summarizes the LC retention times (R t ), accurate masses, chemical formulae, and postulated molecular structures of the nomifensine monooxygenated metabolites identified in human liver microsomes. Six monooxygenated metabolites (H1, H2, H4, H6, H7, and H8) are reported here. Although metabolites H3 and H5 were detected (Fig. 2) , these C ring hydroxylated products are not further biotransformed to reactive metabolites and so are not discussed here. Metabolites H1, H4, and H6 were not very stable at room or higher temperatures and needed to be handled at lower temperature. LC-MS chromatograms of the monooxygenated metabolites of nomifensine from human liver microsomal incubations, taken in full-scan positive ion mode, indicated that metabolites H1 to H8 form protonated ions [M ϩ H] ϩ at m/z 255. Accurate mass measurement of these ions is consistent with the chemical formula of [C 16 H 19 
ϩ , suggesting the introduction of an oxygen atom ( Table 1) .
Formation of Monooxygenated Metabolites (H7 and H8) from Nomifensine in Human Liver Microsomes and cDNA-Expressed Human FMOs and Their Lack of Reaction with GSH. H7 and H8 were found in human liver microsomes in the absence of NADPH at ϳ50% of the levels found in the samples with NADPH (Supplemental Table S1 ). Levels of H7 and H8 similar to those seen in the human liver microsomal incubations containing NADPH were seen in reactions performed with human liver microsomes preincubated with 1-aminobenzotriazole (1 mM) and NADPH (5 mM) for 20 min to inhibit P450 activity (Supplemental Table S1 ). This finding suggests that H7 and H8 are probably not formed significantly by P450s but primarily by FMOs. Because FMOs already exist in their fully catalytic form for the first round of oxidation, some H7 and H8 can be formed in the absence of NADPH.
Scheme 1 summarizes the metabolic pathways of the formation of nomifensine monooxygenated metabolites and GSH adducts to nomifensine oxidative products and the enzymes involved in the corresponding oxidation reactions. Substantial amounts of H7 and H8, but We previously reported that GSH adducts to nomifensine oxidative metabolites were not observed in incubations of nomifensine with human liver microsomes that contained GSH but lacked NADPH (Yu et al., 2010) . H7 and H8 are the only monooxygenated metabolites identified in the incubation of nomifensine with human liver microsomes in the absence of NADPH. Thus, H7 and H8 do not appear to be involved in the formation of the GSH adducts identified in human liver microsomes (Scheme 1, pathway a). Although glutathione conjugation is catalyzed by glutathione transferases, it proceeds at measurable rates via direct chemical reaction (Silverman, 2004) , allowing GSH conjugates to be detected from recombinant microsomal incubations performed in the presence of NADPH and GSH. Therefore, the results that no GSH adduct was detected in incubations of nomifensine with cDNA-expressed human FMOs in the presence of NADPH and GSH supported the conclusion that H7 and H8 do not form reactive metabolites that react with GSH. metabolites H1, H4, H6, H7, and H8. H7 and H8 were only formed in minor amounts. The highest mass responses (and therefore the assumed highest concentrations) measured for H1, H4, and H6 were in nomifensine incubations with CYP3A4, CYP2C19, and CYP2B6, respectively (Fig. 3) .
Formation of GSH adducts in cDNA-expressed human P450 systems in the presence of NADPH and GSH. The formation of nomifensine GSH adducts was evaluated in incubations of nomifensine with Supersomes in the presence of NADPH and GSH and compared with the results in human liver microsomes (Fig. 4A) . In the incuba -FIG. 3 . LC-MS extracted total ion chromatogram of the monooxygenated metabolites of nomifensine from the incubations of nomifensine (100 M) with the human cytochrome P450 expression system in the presence of NADPH at 37°C for 30 min. Data were filtered to show only monooxygenated metabolites. A, in CYP2B6, H6 is the major metabolite. H4 also is significant. B, in CYP2C19, H4 is the major metabolite. H6 also is significant. C, in CYP3A4, H1 is the major metabolite. H4, H6, and H8 are significant.
FIG. 4.
Comparative LC-MS extracted total ion chromatogram of the GSH conjugates of the nomifensine oxidative metabolites from the incubations of nomifensine (100 M) with human liver microsomes and human cytochrome P450 expression systems in the presence of NADPH and GSH at 37°C for 30 min. Data were filtered to show only GSH conjugates. A, LC-MS extracted total ion chromatogram of the GSH conjugates from the incubations of nomifensine (100 M) with human liver microsomes (0.5 mg protein/ml) (Yu et al., 2010) . B, LC-MS extracted total ion chromatogram of the GSH conjugates from the incubations of nomifensine (100 M) with cDNA-expressed human CYP2B6 (100 pmol protein/ml). C, LC-MS extracted total ion chromatogram of the GSH conjugates from the incubations of nomifensine (100 M) with cDNAexpressed human CYP2C19 (100 pmol protein/ml). D, LC-MS extracted total ion chromatogram of the GSH conjugates from the incubations of nomifensine (100 M) with cDNA-expressed human CYP3A4 (100 pmol protein/ml). tion of nomifensine with CYP2B6 in the presence of NADPH, H6 was identified as a major metabolite, and H4 also was significant (Fig.  3A) . When GSH was added to the incubation, nomifensine GSHsulfinamides (M1 and M2) were identified as the predominant GSH adducts (Fig. 4B) . Only trace amounts of M4 and M5 were detected. This finding supports the hypothesis that M1 and M2 are formed through the reaction of GSH with the oxidative product of H6 (Scheme 1, pathway b). In incubations of nomifensine with CYP2C19 in the presence of NADPH, H4 was identified as a major metabolite, and H6 also was a significant product (Fig. 3B) . When GSH was added to the incubation mixture, in addition to M1 and M2, significant amounts of the C-linked GSH adducts, M3, M4, M5, and M6, also were identified (Fig. 4C) . This result suggests that H4 is linked to the formation of the GSH adducts, M3 to M6 (Scheme 1, pathway c). In the incubation of nomifensine with CYP3A4 in the presence of NADPH, H1 was identified as a major metabolite and levels of H4 and H6 also were significant (Fig. 3C) . With the addition of GSH, in addition to M1 to M6, another group of C-linked GSH adducts (M7 to M9) were detected that were distinct from those formed in CYP2C19 (Fig. 4D) . This result suggests that the formation of H1 is linked to the formation of GSH adducts, M7, M8, and M9 (Scheme 1, pathway d).
Identification of the Major P450 Isoforms Involved in the Formation of Monooxygenated Metabolites H1, H4, and H6. Relative activity of the P450s that metabolize nomifensine to H1, H4, and H6.
As shown in Fig. 5 , the relative activity of the P450s that metabolize nomifensine to H1 is ranked in descending order of CYP3A4, CYP3A5, CYP1A1, CYP1A2, CYP2B6, and CYP2C19. Other P450 isoforms (CYP2A6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1) showed either no or minimal (Ͻ0.5% of the activity observed with CYP3A4) activities toward the formation of H1. The relative activity of the P450s that metabolize nomifensine to H4 is ranked in descending order of CYP2C19, CYP2B6, CYP1A2, CYP3A4, CYP2C9, CYP3A5, and CYP2D6 (Fig. 6 ). Other P450 isoforms (CYP1A1, CYP2A6, CYP2C8, and CYP2E1) showed either no or minimal (Ͻ0.5% of the activity observed with CYP2C19) activities toward the formation of H4. The activity of the P450s that metabolize nomifensine to H6 is ranked in descending order of CYP2B6, CYP2C19, CYP1A2, CYP3A4, CYP3A5, CYP2C9, and CYP1A1 (Fig. 7) . Other P450 isoforms (CYP2A6, CYP2C8, CYP2D6, and CYP2E1) showed either no or minimal (Ͻ0.5% of the activity observed with CYP2B6) activities toward the formation of H6.
Inhibition of the formation of monooxygenated metabolites (H1, H4, and H6) in human liver microsomes. The inhibitory effects of monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 on the production of H1, H4, and H6 were examined by using human liver microsomes as the enzyme source and nomifensine as the substrate in the presence of NADPH as shown in Table 2 . The relative inhibition percentages of H6 formation using monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 were 4.6, 63, 9.9, and 0%, respectively, suggesting that CYP2B6 is primarily responsible for the formation of H6 in human liver microsomes (Scheme 1, pathway b). The inhibition effect on the formation of H6 by the combination of the four monoclonal antibodies was 74%. FIG. 5 . Relative metabolite H1 formation activities in human cytochrome P450 (CYP) expression systems in the presence of NADPH. The assays were performed using nomifensine and microsomes from baculovirus/insect cells expressing human cytochrome P450 (Supersomes, 100 pmol protein/ml). The calibration curve was prepared through the systematic dilution of the reconstituted incubation mixture of nomifensine in CYP3A4 under the same experimental conditions. Results less than 0.5% of the concentration observed in CYP3A4 sample are not shown in the graph.
FIG. 6. Relative metabolite H4 formation activities in human cytochrome P450
(CYP) expression systems in the presence of NADPH. The assays were performed using nomifensine and microsomes from baculovirus/insect cells expressing human cytochrome P450 (Supersomes, 100 pmol protein/ml). The calibration curve was prepared through the systematic dilution of the reconstituted incubation mixture of nomifensine in CYP2C19 under the same experimental conditions. Results less than 0.5% of the concentration observed in CYP2C19 sample are not shown in the graph.
FIG. 7.
Relative metabolite H6 formation activities in human cytochrome P450 (CYP) expression systems in the presence of NADPH. The assays were performed using nomifensine and microsomes from baculovirus/inset cells expressing human cytochrome P450 (Supersomes, 100 pmol protein/ml). The calibration curve was prepared through the systematic dilution of the reconstituted incubation mixture of nomifensine CYP2B6 under the same experimental conditions. Results less than 0.5% of the concentration observed in CYP2B6 sample are not shown in the graph. 
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The relative inhibition percentages of H4 formation using monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 were 27, 12, 22, and 0%, respectively ( Table 2 ), suggesting that CYP2C19, CYP1A2, and CYP2B6 were only partially responsible for the formation of H4 in human liver microsomes. The inhibition effect on the formation of H4 by the combination of the four monoclonal antibodies was only 57%, suggesting that other unidentified human liver microsomal enzymes may also catalyze this oxidation reaction (Scheme 1, pathway c).
The relative inhibition percentages of H1 formation using monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 were 7.8, 8.2, 11, and 62%, respectively ( Table 2 ), suggesting that CYP3A4 is primarily responsible for the formation of H1 in human liver microsomes (Scheme 1, pathway d). The inhibition effect on the formation of H1 by the combination of the four monoclonal antibodies was 79%.
Inhibition of the Formation of GSH Conjugates (M1 and M2) in Human Liver Microsomes in the Presence of Monoclonal Anti-P450 Antibodies. The inhibitory effects of monoclonal antibodies to CYP1A2, CYP2B6, CYP2C19, and CYP3A4 on the production of GSH adducts of nomifensine oxidative metabolites were examined in human liver microsomes in the presence of NADPH and GSH. Anti-CYP2B6 and anti-CYP2C19 antibodies inhibited the formation of M1 and M2 by 75 Ϯ 1.3 and 3.8 Ϯ 0.8%, respectively. No significant inhibitory effect was observed for anti-CYP1A2 and anti-CYP3A4. This result supports the mechanism of formation of M1 and M2 through the reaction of GSH with the oxidative product of H6 (Scheme 1, pathway b). The combined inhibitory effect of all four monoclonal antibodies on M1 and M2 formation was 82 Ϯ 1.0%, confirming that the contributions of CYP1A2 and CYP3A4 to the formation of H6 (precursor of M1 and M2) were minimal. Efforts to accurately quantify the inhibitory effects of monoclonal antibodies on the formation of C-linked GSH conjugates M3 to M9 were not successful because of the low levels of these metabolites in the incubation mixtures.
Metabolite Identification. Three types of nomifensine monooxygenated metabolites in human liver microsomal incubations were characterized with respect to mass, chemical formula, and fragmentation pattern on LC-MS/MS. They are C-linked metabolites (H1, H2, H4), N-hydroxylamine (H6), and N-oxides (H7 and H8).
H2, H1, and H4. The UPLC retention time and the mass fragmentation pattern of the molecular ion of H2 (Supplemental Fig. S1 ; Supplemental Scheme S1; Supplemental Table S2 ) are the same as those of the synthetic standard I, providing strong evidence that H2 is the 4-hydroxylated metabolite of nomifensine with the oxygen atom substituted in the C ring (Scheme 1, pathway e). The collision-induced dissociation (CID) mass spectrum of the molecular ion of H1 revealed product ions at m/z 224, 212, 196, 177, 146, 134, 122, and 91 (Fig. 8 ; Supplemental Table S3 ). Based on the similar fragmentation patterns of nomifensine (Yu et al., 2010) and H2, the ion at m/z 212 is probably formed through a retro Diels-Alder reaction (Fig. 8, pathway a) . The cross-ring cleavage at N(2)-C(1) and N(2)-C(3) bonds generates ions at m/z 224 (Fig. 8, pathway b) . The cleavage of the bond between C(4) and the phenyl ring (C ring) leads to the formation of an ion at m/z 177 (Fig. 8, pathway c) . Further fragmentation of the ion at m/z 224 leads to the formation of product ions at m/z 196, 146, and 91, corresponding to the losses of CO, C 6 H 6 , and C 8 H 7 NO, respectively, suggesting that the oxygen atom is substituted on the A ring. The major fragmentation pathways of the molecular ion of H4 are similar to those seen in H1, indicating a similar modification to the A ring ( Fig. 9 ; Supplemental Table S4 ). The subtle difference between the spectra (m/z 238, 207, and 195 in the mass spectra of H4) suggests it is a regio-isomer of H1.
H6. The CID mass spectrum of the molecular ion of H6 revealed product ions at m/z 238, 237, 223, 212, 209, 195, and 146 (Fig. 10 ; Supplemental Table S5 (Table 1; Supplemental Table S3 ). The inset shows the proposed fragmentation pathways of the molecular ion [M ϩ H] ϩ of H1 at m/z 255.
H6 leads to the formation of an odd-electron ion at m/z 238. The further loss of CH 3 ⅐ and H⅐ radicals from m/z 238 generates characteristic ions at m/z 223 and 237, respectively (Fig. 10, pathways a and  b) . The odd-electron ions at m/z 195 and 209 are likely to be formed from the ion at m/z 238 through a retro Diels-Alder reaction (Fig. 10 , pathway c) and a cross-ring cleavage at N(2)-C(1) and N(2)-C(3) bonds (Fig. 10, pathway d) , respectively. The mass spectra of H6 suggest that the metabolite is the N-hydroxylamine of nomifensine.
H7 and H8. The CID mass spectrum of the molecular ion of H8 revealed product ions at m/z 238, 237, 223, 221, 209, 208, 196, 195, 194, 179, 160, and 146 (Fig. 11; Supplemental Table 6S (Table 1; Supplemental Table S5) water, respectively, from the molecular ion of H8 ( Fig. 11 ; Supplemental Scheme S2, pathways a and b). The cleavage of the bond between C(4) and the phenyl ring (C ring) and the loss of the hydroxyl radical leads to the formation of an odd-electron ion at m/z 160 ( Fig. 11 ; Supplemental Scheme S2, pathway c). The cross-ring cleavage of the molecular ion at m/z 255 at N(2)-C(1) and N(2)-C(3) bonds and the loss of a hydroxyl radical yields an ion at m/z 209 ( Fig. 11 ; Supplemental Scheme S2, pathway d). The ion at m/z 196 appears to be formed through a retro Diels-Alder reaction plus a loss of the N-oxide oxygen ( Fig. 11 ; Supplemental Scheme S2, pathway e). The mass spectra of H8 suggest that it is the N-oxide of nomifensine. H7 is a diastereomer of H8 (Supplemental Fig. 2S ; Supplemental Table 7S ).
Discussion
This study reports the identification of new nomifensine monooxygenated metabolites (H1, H4, H6, H7, and H8) and characterizes the major enzymes involved in the formation of these metabolites. In addition, the bioactivation pathways that lead to the formation of GSH conjugates in human liver microsomes are revealed.
Incubations of nomifensine with a panel of cDNA-expressed human P450s indicated that CYP2B6 has the highest activity toward the formation of H6. The observed activity was further confirmed by inhibition studies using human liver microsomes and monoclonal anti-P450 antibodies. The anti-CYP2B6 antibody inhibited the formation of H6 by ϳ63%, suggesting that CYP2B6 is the major P450 isoform responsible for the formation of H6.
Substantial amounts of nomifensine GSH-sulfinamides formed in cDNA-expressed human CYP2B6 in the presence of NADPH and GSH and the strong inhibition of the formation of these GSH adducts in human liver microsomes in the presence of NADPH, GSH, and monoclonal anti-CYP2B6 antibody suggested that H6 was further oxidized to reactive product in human liver microsomes, which reacted with GSH, leading to the formation of nomifensine GSH-sulfinamides.
The in vitro experimental results described here may help to explain some of the clinical toxicological results. It was reported that CYP2B6 is highly polymorphically expressed and is inducible (Shimada et al., 1994; Lang et al., 2004) , and hepatic CYP2B6 accounts for ϳ6% of total microsomal P450s (Stresser and Kupfer, 1999) . CYP2B6 activities have been reported to vary from 25-fold when S-mephenytoin is used as a probe substrate (Ekins et al., 1998) to 80-fold when bupropion is used as model substrate (Faucette et al., 2000) . Although these interindividual differences in CYP2B6 expression and catalytic activity would not be expected to cause significant differences in nomifensine clinical pharmacokinetics, because the major metabolic pathway in human is direct N-glucuronidation at the aniline nitrogen of the molecule (Heptner et al., 1978; Hornke et al., 1980; Lindberg and Syvälahti, 1986) , it may lead to substantial differences in the toxicities of nomifensine if the N-hydroxylamine is an important contributor to these toxicities.
Although CYP2C19 showed the highest activity toward the formation of H4 among the cDNA-expressed human P450 isoforms that were tested, the monoclonal anti-CYP2C19 antibody only inhibited the formation of H4 by ϳ22%, suggesting that CYP2C19 only partially contributed to the formation of H4. CYP1A2 also was substantially involved in this reaction. Because the inhibitory effect on the formation of H4 by the combination of four antibodies was ϳ57%, other unidentified enzyme(s) may also be involved in this oxidative process.
GSH adduct formation in cDNA-expressed human CYP2C19 compared with that found in CYP2B6 in the presence of NADPH and GSH suggested that H4 was further oxidized and formed a group of nomifensine C-linked GSH adducts (M3, M4, M5, and M6). Mass spectra of these GSH adducts showed that M3 and M4 are probably regio-selective isomers of M5 and M6, whereas M3 and M4 or M5 and M6 are probably diasteromers (Yu et al., 2010) . Being an aromatic system, the epoxidation at the A ring is a likely initial bioactivation step before the formation of these GSH adducts (Scheme 2, pathway a). Based on the structure of H4, which is related to the oxidation at the arene ring of the aromatic amine, another pathway may also be possible for the formation of these GSH adducts (Scheme 2, pathway b). Similar to acetaminophen (Rosen et al., 1983; Thummel et al., 1993; Nelson, 1995) , nomifensine radicals could be generated through a cytochrome P450-dependent hydrogen atom abstraction. After the second electron transfer, an electrophilic intermediate (nomifensine benzoquinone imine) might be formed. The 1,4-addition of GSH to this nomifensine benzoquinone imine would then lead to FIG. 11 . Product ion mass spectrum obtained by CID of the molecular ion of metabolite H8 (R t ϭ 12.99 min) at m/z 255 from NADPHsupplemented human liver microsomal incubations containing nomifensine (40 M) (Table 1;  Supplemental Table S6 ).
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at ASPET Journals on June 22, 2017 dmd.aspetjournals.org the formation of C-linked GSH adducts. The regio-isomers could be generated through the attack of the GS moiety to the two available positions of the para-or ortho-benzoquinone imine. Another possibility is formation of the ipso adducts through 1,2-addition of GSH to the 5-or 8-position of the nomifensine benzoquinone imine intermediate followed by intramolecular rearrangement by a 1,2-shift of the glutathionyl moiety of the nomifensine ipso adducts (Chen et al., 1999) . Because nomifensine is a racemic mixture, extra chiral centers are introduced into the molecule when nomifensine reacts with optically pure GSH, leading to the formation of diastereomers.
Incubations of nomifensine with cDNA-expressed human P450s indicated that CYP3A4 has the highest activity toward the formation of H1. The observed activity was further confirmed by inhibition studies using human liver microsomes and monoclonal anti-P450 antibodies. Anti-CYP3A4 antibody inhibited the formation of H1 by ϳ62%, suggesting that CYP3A4 is the major P450 isoform in the formation of H1.
GSH adducts formed in cDNA-expressed human CYP3A4 compared with those found in CYP2C19 and CYP2B6 in the presence of NADPH and GSH suggested that H1 was linked to the formation of another group of nomifensine C-linked GSH adducts (M7, M8, and M9). Because the hydroxylation at H1 is on the A ring, these GSH adducts may be formed through the mechanisms similar to those observed with M3 to M6.
CYP3A4 activity also varies considerably among individuals because of the effects of genetic polymorphisms or exposure to drugs, dietary factors, or hormones that are inducers or inhibitors of CYP3A4. Therefore, substantial differences in the toxicities of nomifensine may result from the formation of C-linked monooxygenated metabolite H1 if this bioactivation pathway is an important contributor to these toxicities. Metabolite identification indicates that the hydroxylation at H1 and H4 is not on the C ring, suggesting that the C-linked GSH conjugates (M3 to M9) are not formed through quinone-methide intermediate (the oxidative product of I).
In conclusion, metabolite identification revealed three new types of nomifensine monooxygenated metabolites in human liver microsomes. First, the oxidation at the A ring of nomifensine leads to the formation of C-linked hydroxylated metabolites (H1 and H4). Second, aniline oxidation yields an N-hydroxylamine (H6). Third, the oxidation at the nitrogen atom in the 1,2,3,4-tetrahydroisoquinoline ring produces nomifensine N-oxides (H7 and H8). The metabolism studies on GSH adduct formation in cDNA-expressed human CYP2B6, CYP2C19, and CYP3A4 in the presence of NADPH and GSH suggest that the nomifensine GSH-sulfinamides were formed through the reaction between GSH and the oxidative product of H6. The C-linked GSH adducts M3, M4, M5, and M6 may be formed through the epoxidation pathway and/or through the 1,4-or 1,2-addition of GSH to the nomifensine benzoquinone imine intermediate, which can be produced through hydrogen atom abstraction mechanism via radicals of H4. C-linked GSH adducts M7, M8, and M9 may be formed through similar mechanisms via H1. Nomifensine N-oxides (H7 and H8) do not form reactive metabolites that react with GSH. Metabolism studies in cDNA-expressed human cytochrome P450s and inhibition studies in human liver microsomes in the presence and absence of monoclonal anti-P450 antibodies showed that CYP3A4 and CYP2B6 contributed primarily to the formation of H1 and H6, respectively. The results also indicated that CYP2C19, CYP1A2, CYP2B6, and other unidentified enzyme(s) were involved in the formation of H4. Finally, metabolism studies in cDNA-expressed human FMOs showed that H7 and H8 are formed almost exclusively via the catalysis of FMO3, FMO1, and FMO5 and not P450s. These results suggest that more than one nomifensine bioactivation pathway may lead to the clinical observations of nomifensine toxicities. In addition, because some of the bioactivation pathways are catalyzed primarily by a single P450 isozyme that is both polymorphically expressed and inducible, the toxicities caused by each of these bioactivation pathways may show substantial differences in vivo. The calculated values were mean ± S.D. of three experiments. Table 1 and S2, Scheme S1). When the incubation mixture was separated on a UPLC column using deuterated mobile phase, H1, H2, and H4 showed a mass change of 4 Da. This indicated that H1, Table 1 and S7, Scheme S2). When the incubation mixture was separated on a UPLC column using deuterated mobile phase, H6 to H8 showed a mass change of 3 Da. This indicated that H6, H7 and H8 are nomifensine N-oxidation products.
